Citations Appearing in 2018

  1. Abodakpi, H., Chang, K.T., Gao, S., Sánchez-Díaz, A.M., Cantón, R. and Tam, V.H., 2018. Optimal Piperacillin/Tazobactam Dosing Strategies against ESBL-producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy.
  2. Ayyar, V. S.; Sukumaran, S.; DuBois, D. C.; Almon, R. R.; Jusko, W. J. Modeling Corticosteroid Pharmacogenomics and Proteomics in Rat Liver. J. Pharmacol. Exp. Ther. 2018, 367 (1), 168–183.
  3. Ayyar, V. S.; Sukumaran, S.; DuBois, D. C.; Almon, R. R.; Qu, J.; Jusko, W. J. Receptor/Gene/Protein-Mediated Signaling Connects Methylprednisolone Exposure to Metabolic and Immune-Related Pharmacodynamic Actions in Liver. J. Pharmacokinet. Pharmacodyn. 2018, 45 (4), 557–575.
  4. Bacher, J., Avila, N.A. and Walsh, T.J., 2018. Investigate the performance of non-invasive diagnostic tests such as galactomannan enzyme immunoassay and quantitative Caspofungin in the early diagnosis of invasive aspergillosis (IA).
  5. Badders, N. M.; Korff, A.; Miranda, H. C.; Vuppala, P. K.; Smith, R. B.; Winborn, B. J.; Quemin, E. R.; Sopher, B. L.; Dearman, J.; Messing, J. Selective Modulation of the Androgen Receptor AF2 Domain Rescues Degeneration in Spinal Bulbar Muscular Atrophy. Nat. Med. 2018, 24 (4), 427.
  6. Baek, I. Dose Proportionality and Pharmacokinetics of Dronedarone Following Intravenous and Oral Administration to Rat. Xenobiotica 2018, 1–6.
  7. Bourne, D. A. Mathematical Modeling of Pharmacokinetic Data; Routledge, 2018.
  8. Box, H.; Negri, C.; Livermore, J.; Whalley, S.; Johnson, A.; McEntee, L.; Alastruey-Izquierdo, A.; Meis, J. F.; Thornton, C.; Hope, W. Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. Antimicrob. Agents Chemother. 2018, 62 (5).
  9. Boyanapalli, S. S. S.; Huang, Y.; Su, Z.; Cheng, D.; Zhang, C.; Guo, Y.; Rao, R.; Androulakis, I. P.; Kong, A. Pharmacokinetics and Pharmacodynamics of Curcumin in Regulating Anti‐inflammatory and Epigenetic Gene Expression. Biopharm. Drug Dispos. 2018, 39 (6), 289–297.
  10. Cabel, L.; Blanchet, B.; Thomas‐Schoemann, A.; Huillard, O.; Bellesoeur, A.; Cessot, A.; Giroux, J.; Boudou‐Rouquette, P.; Coriat, R.; Vidal, M. Drug Monitoring of Sunitinib in Patients with Advanced Solid Tumors: A Monocentric Observational French Study. Fundam. Clin. Pharmacol. 2018, 32 (1), 98–107.
  11. Cabrera-Pérez, M. Á.; Pham-The, H. Computational Modeling of Human Oral Bioavailability: What Will Be Next? Expert Opin. Drug Discov. 2018, 13 (6), 509–521.
  12. Cooper, I., Landersdorfer, C.B., St John, A.G. and Graudins, A., 2018. The pharmacokinetics of intranasal droperidol in volunteers characterised via population modelling. SAGE Open Medicine, 6, p.2050312118813283.
  13. Craigmill, A.L., 2018. Handbook of comparative pharmacokinetics and residues of veterinary therapeutic drugs. CRC press.
  14. Dave, V., Yadav, R.B., Yadav, S., Sharma, S., Sahu, R.K. and Ajayi, A.F., A Critique of Computer Simulation Software’s Used in Pharmacokinetics and Pharmacodynamics Analysis. Current Clinical Pharmacology, 2018, 13(4), pp.216-235.
  15. de Mello, C. P. P.; Tao, X.; Kim, T. H.; Bulitta, J. B.; Rodriquez, J. L.; Pomeroy, J. J.; Brown, A. N. Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens. Antimicrob. Agents Chemother. 2018, 62 (1).
  16. de Mello, C. P. P.; Tao, X.; Kim, T. H.; Vicchiarelli, M.; Bulitta, J. B.; Kaushik, A.; Brown, A. N. Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model. Antimicrob. Agents Chemother. 2018, 62 (9).
  17. de Miranda Silva, C.; Hajihosseini, A.; Myrick, J.; Nole, J.; Louie, A.; Schmidt, S.; Drusano, G. L. Effect of Linezolid plus Bedaquiline against Mycobacterium Tuberculosis in Log-Phase, Acid-Phase and Non-Replicating-Persister (NRP)-Phase in an In Vitro Assay. Antimicrob. Agents Chemother. 2018, 62 (8).
  18. Deshpande, D., Pasipanodya, J.G., Srivastava, S., Bendet, P., Koeuth, T., Bhavnani, S.M., Ambrose, P.G., Smythe, W., McIlleron, H., Thwaites, G. and Gumusboga, M.  Gatifloxacin pharmacokinetics/pharmacodynamics–based optimal dosing for pulmonary and meningeal multidrug-resistant tuberculosis. Clinical Infectious Diseases, 2018, 67(suppl_3), pp.S274-S283.
  19. Deshpande, D., Pasipanodya, J.G., Mpagama, S.G., Bendet, P., Srivastava, S., Koeuth, T., Lee, P.S., Bhavnani, S.M., Ambrose, P.G., Thwaites, G. and Heysell, S.K. Levofloxacin pharmacokinetics/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis. Clinical Infectious Diseases, 2018, 67(suppl_3), pp.S293-S302.
  20. Deshpande, D., Srivastava, S., Nuermberger, E., Koeuth, T., Martin, K.R., Cirrincione, K.N., Lee, P.S. and Gumbo, T. Multiparameter responses to tedizolid monotherapy and moxifloxacin combination therapy models of children with intracellular tuberculosis. Clinical Infectious Diseases, 2018, 67(suppl_3), pp.S342-S348.
  21. Dheda, K.; Lenders, L.; Magombedze, G.; Srivastava, S.; Raj, P.; Arning, E.; Ashcraft, P.; Bottiglieri, T.; Wainwright, H.; Pennel, T. Drug Penetration Gradients Associated with Acquired Drug Resistance in Tuberculosis Patients. Am. J. Respir. Crit. Care Med. 2018.
  22. Diep, J. K.; Forrest, A.; Krzyzanski, W.; van Hasselt, C.; Russo, T. A.; Rao, G. G. Mechanism‐Based Disease Progression Model Describing Host‐Pathogen Interactions During the Pathogenesis of Acinetobacter Baumannii Pneumonia. CPT Pharmacometrics Syst. Pharmacol. 2018, 7 (8), 507–516.
  23. Drusano, G. L.; Myrick, J.; Maynard, M.; Nole, J.; Duncanson, B.; Brown, D.; Schmidt, S.; Neely, M.; Scanga, C. A.; Peloquin, C. Linezolid Kills Acid Phase and Non-Replicative Persister Phase Mycobacterium Tuberculosis in a Hollow Fiber Infection Model. Antimicrob. Agents Chemother. 2018, 62 (8).
  24. Erlandsen, M.; Martinussen, C.; Gravholt, C. H. Integrated Model of Insulin and Glucose Kinetics Describing Both Hepatic Glucose and Pancreatic Insulin Regulation. Comput. Methods Programs Biomed. 2018, 156, 121–131.
  25. Follman, K. E.; Dave, R. A.; Morris, M. E. Effects of Renal Impairment on Transporter‐mediated Renal Reabsorption of Drugs and Renal Drug–drug Interactions: A Simulation‐based Study. Biopharm. Drug Dispos. 2018, 39 (4), 218–231.
  26. Gergs, U.; Ihlefeld, D.; Clauss, T.; Weiss, M.; Pönicke, K.; Hofmann, G. O.; Neumann, J. Population Pharmacokinetics of Levofloxacin in Plasma and Bone of Patients Undergoing Hip or Knee Surgery. Clin. Pharmacol. drug Dev. 2018, 7 (7), 692–698.
  27. Glatting, G. Radiation Dosimetry in Ibritumomab Therapy. In Resistance to Ibritumomab in Lymphoma 2018, 105–117.
  28. Guyot, L.; Honorat, M.; Jacob, G.; Bardel, C.; Tod, M.; Puisieux, A.; Guitton, J.; Payen, L. Toxicokinetics and Tolerance of a High Energy Material 3, 4, 5-Trinitropyrazole (TNP) in Mice. Toxicol. Appl. Pharmacol. 2018, 355, 103–111.
  29. He, H.; Liu, C.; Wu, Y.; Zhang, X.; Fan, J.; Cao, Y. A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore Its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts. Pharm. Res. 2018, 35 (9), 174.
  30. Hecht, M.; Veigure, R.; Couchman, L.; S Barker, C. I.; Standing, J. F.; Takkis, K.; Evard, H.; Johnston, A.; Herodes, K.; Leito, I. Utilization of Data below the Analytical Limit of Quantitation in Pharmacokinetic Analysis and Modeling: Promoting Interdisciplinary Debate. Bioanalysis 2018, 10 (15), 1229–1248.
  31. Horkovics-Kovats, S. Comparison of Dissolution Time Profiles: No Similarity but Where Is the Difference? Eur. J. Pharm. Sci. 2018, 121, 9–15.
  32. Horkovics-Kovats, S.; Ulč, I.; Vít, L.; Němec, B.; Rada, V. Physicochemical Pharmacokinetics as an Optimization Tool for Generic Development: A Case Study. Eur. J. Pharm. Sci. 2018, 111, 349–357.
  33. Hosseini, I.; Gajjala, A.; Yadav, D. B.; Sukumaran, S.; Ramanujan, S.; Paxson, R.; Gadkar, K. GPKPDSim: A SimBiology®-Based GUI Application for PKPD Modeling in Drug Development. J. Pharmacokinet. Pharmacodyn. 2018, 45 (2), 259–275.
  34. Hou, C., Liu, W., Liang, Z., Han, W., Li, J., Ye, L., Liu, M., Cai, Z., Zhao, J., Chen, Y. and Liu, S. UGT-mediated metabolism plays a dominant role in the pharmacokinetic behavior and the disposition of morusin in vivo and in vitro. Journal of pharmaceutical and biomedical analysis, 2018, 154, pp.339-353.
  35. Jiao, Y.; Kim, T. H.; Tao, X.; Kinzig, M.; Landersdorfer, C. B.; Drescher, S. K.; Sutaria, D. S.; Moya, B.; Holzgrabe, U.; Sörgel, F. First Population Pharmacokinetic Analysis Showing Increased Quinolone Metabolite Formation and Clearance in Patients with Cystic Fibrosis Compared to Healthy Volunteers. Eur. J. Pharm. Sci. 2018, 123, 416–428.
  36. Illamola, S.M., Sherwin, C.M. and van Hasselt, J.C. Clinical pharmacokinetics of amikacin in pediatric patients: a comprehensive review of population pharmacokinetic analyses. Clinical pharmacokinetics, 2018, 57(10), pp.1217-1228.
  37. Inaba, H., Cao, X., Han, A.Q., Panetta, J.C., Ness, K.K., Metzger, M.L., Rubnitz, J.E., Ribeiro, R.C., Sandlund, J.T., Jeha, S. and Cheng, C.. Bone mineral density in children with acute lymphoblastic leukemia. Cancer, 2018, 124(5), pp.1025-1035.
  38. Kim, M.-S.; Baek, I. Effect of Dronedarone on the Pharmacokinetics of Carvedilol Following Oral Administration to Rats. Eur. J. Pharm. Sci. 2018, 111, 13–19.
  39. Kim, J.S., Kim, M.S. and Baek, I.H. Enhanced bioavailability of tadalafil after intranasal administration in beagle dogs. Pharmaceutics, 2018, 10(4), p.187.
  40. Kuti, J. L.; Pettit, R. S.; Neu, N.; Cies, J. J.; Lapin, C.; Muhlebach, M. S.; Novak, K. J.; Nguyen, S. T.; Saiman, L.; Nicolau, D. P. Meropenem Time above the MIC Exposure Is Predictive of Response in Cystic Fibrosis Children with Acute Pulmonary Exacerbations. Diagn. Microbiol. Infect. Dis. 2018, 91 (3), 294–297.
  41. Lakota, E. A.; Landersdorfer, C. B.; Nation, R. L.; Li, J.; Kaye, K. S.; Rao, G. G.; Forrest, A. Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm. Antimicrob. Agents Chemother. 2018, 62 (7).
  42. Lakota, E. A.; Ong, V.; Flanagan, S.; Rubino, C. M. Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data. Antimicrob. Agents Chemother. 2018, 62 (6).
  43. Landersdorfer, C. B.; Rees, V. E.; Yadav, R.; Rogers, K. E.; Kim, T. H.; Bergen, P. J.; Cheah, S.-E.; Boyce, J. D.; Peleg, A. Y.; Oliver, A. Optimization of a Meropenem plus Tobramycin Combination Dosage Regimen against Hypermutable and Non-Hypermutable Pseudomonas Aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. Antimicrob. Agents Chemother. 2018, 62 (4).
  44. Landersdorfer, C.B., Wang, J., Wirth, V., Chen, K., Kaye, K.S., Tsuji, B.T., Li, J. and Nation, R.L. Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. Journal of Antimicrobial Chemotherapy, 2018, 73(2), pp.462-468.
  45. Landersdorfer, C. B.; Yadav, R.; Rogers, K. E.; Kim, T. H.; Shin, B. S.; Boyce, J. D.; Nation, R. L.; Bulitta, J. B. Combating Carbapenem-Resistant Acinetobacter Baumannii by an Optimized Imipenem plus Tobramycin Dosage Regimen–prospective Validation via Hollow Fiber Infection and Mathematical Modeling. Antimicrob. Agents Chemother. 2018, 62 (4).
  46. Larizza, C.; Borella, E.; Pasotti, L.; Tartaglione, P.; Smith, M.; Moodie, S.; Magni, P. Complex Bayesian Modeling Workflows Encoding and Execution Made Easy With a Novel WinBUGS Plugin of the Drug Disease Model Resources Interoperability Framework. CPT pharmacometrics Syst. Pharmacol. 2018, 7 (5), 298–308.
  47. Leijenaar, J. F.; Groeneveld, G. J.; van der Flier, W. M.; Scheltens, P.; Klaassen, E. S.; Weinstein, H. C.; Biessels, G. J.; Barkhof, F.; Prins, N. D. Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. JMIR Res. Protoc. 2018, 7 (3).
  48. Li, P.; Li, S.; Gu, H.; Lu, Q.; Jiang, W.; Pei, X.; Sun, Y.; Xu, H.; Wang, G.; Hao, K. The Exposure-Effect-Toxicity Correlation of Docetaxel and Magnesium Isoglycyrrhizinate in Non-Small Cell Lung Tumor-Bearing Mice. Biomed. Pharmacother. 2018, 97, 1000–1010.
  49. Lim, T.-P.; Wang, R.; Poh, G. Q.; Koh, T.-H.; Tan, T.-Y.; Lee, W.; Teo, J. Q.-M.; Cai, Y.; Tan, T.-T.; Ee, P. L. R. Integrated Pharmacokinetic–pharmacodynamic Modeling to Evaluate Empiric Carbapenem Therapy in Bloodstream Infections. Infect. Drug Resist. 2018, 11, 1591.
  50. Lin, Y.-W.; Heidi, H. Y.; Zhao, J.; Han, M.-L.; Zhu, Y.; Akter, J.; Wickremasinghe, H.; Walpola, H.; Wirth, V.; Rao, G. G. Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensive Drug-Resistant Pseudomonas Aeruginosa. Antimicrob. Agents Chemother. 2018, 62 (6).
  51. Lin, Y.-W.; Zhou, Q. T.; Han, M.-L.; Onufrak, N. J.; Chen, K.; Wang, J.; Forrest, A.; Chan, H.-K.; Li, J. Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model. Antimicrob. Agents Chemother. 2018, 62 (3).
  52. Louie, A.; Duncanson, B.; Myrick, J.; Maynard, M.; Nole, J.; Brown, D.; Schmidt, S.; Neely, M.; Scanga, C. A.; Peloquin, C. The Activity of Moxifloxacin against Acid-Phase and Non-Replicative Persister Phenotype Phase Mycobacterium Tuberculosis in a Hollow Fiber Infection Model. Antimicrob. Agents Chemother. 2018.
  53. Luo, D.; Carter, K. A.; Geng, J.; He, X.; Lovell, J. F. Short Drug–Light Intervals Improve Liposomal Chemophototherapy in Mice Bearing MIA PaCa-2 Xenografts. Mol. Pharm. 2018, 15 (9), 3682–3689.
  54. Luu, T.; Kim, K.; Blanchard, S.; Anyang, B.; Hurria, A.; Yang, L.; Beumer, J. H.; Somlo, G.; Yen, Y. Phase IB Trial of Ixabepilone and Vorinostat in Metastatic Breast Cancer. Breast Cancer Res. Treat. 2018, 167 (2), 469–478.
  55. Marahatta, A.; Baek, I. H.; Pyo, J. S.; Bh, B.; Kim, H. K.; Bang, J. S.; Yoon, H.; Rhew, K. Y.; Chai, O. H.; Lee, Y. C. Pharmacokinetics and Bronchopulmonary Disposition of PI3KDelta Inhibitor IC87114 after Intratracheal Administration in a Severe Asthma Model. Indian J. Pharm. Sci. 2018, 79 (6), 994–1000.
  56. Marchand, S.; Boisson, M.; Mehta, S.; Adier, C.; Mimoz, O.; Grégoire, N.; Couet, W. Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 6. Aminoglycosides. Antimicrob. Agents Chemother. 2018, 62 (10).
  57. Methaneethorn, J. Population pharmacokinetic analyses of lithium: a systematic review. European journal of drug metabolism and pharmacokinetics, 2018, 43(1), pp.25-34.
  58. Mizuno, K.; Dong, M.; Fukuda, T.; Chandra, S.; Mehta, P. A.; McConnell, S.; Anaissie, E. J.; Vinks, A. A. Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation. Clin. Pharmacokinet. 2018, 57 (5), 625–636.
  59. Molins, E. A. G.; Jusko, W. J. Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells. AAPS J. 2018, 20 (5), 80.
  60. Muller, A.C., Ducharme, M.P. and Kanfer, I. Identification of mechanism and pathway of the interaction between the African traditional medicine, Sutherlandia Frutescens, and the antiretroviral protease inhibitor, Atazanavir, in human subjects using population pharmacokinetic (PK) analysis. Journal of Pharmacy & Pharmaceutical Sciences, 2018, 21(1s), pp.215s-221s.
  61. Ogenstad, S. A Statistical Approach to Clinical Trial Simulations. In Biopharmaceutical Applied Statistics Symposium; Springer, 2018; pp 1–18.
  62. Ozdin, D., Sharma, N., Lujan-Zilbermann, J., Colucci, P., Kanfer, I. and Ducharme, M.P. Revisiting FDA’s 1995 Guidance on bioequivalence establishment of topical dermatologic corticosteroids: new research based recommendations. Journal of Pharmacy & Pharmaceutical Sciences, 2018, 21, pp.413-428.
  63. Pai, A. B.; Pai, M. P.; Meyer, D. E.; Bales, B. C.; Cotero, V. E.; Zheng, N.; Jiang, W. In Vitro and In Vivo DFO-Chelatable Labile Iron Release Profiles among Commercially Available Intravenous Iron Nanoparticle Formulations. Regul. Toxicol. Pharmacol. 2018, 97, 17–23.
  64. Park, A. young J.; Wang, J.; Jayne, J.; Fukushima, L.; Rao, A. P.; D’Argenio, D. Z.; Beringer, P. M. Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis. Antimicrob. Agents Chemother. 2018, 62 (9).
  65. Patel, K.; Kirkpatrick, C. M. Basic Pharmacokinetic Principles. In Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill; Springer, 2018; pp 1–16.
  66. Pires de Mello, C.P., Drusano, G.L., Rodriquez, J.L., Kaushik, A. and Brown, A.N. Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM). Viruses, 2018, 10(6), p.317.
  67. Polli, J. R.; Engler, F. A.; Balthasar, J. P. Physiologically-Based Modeling of the Pharmacokinetics of “Catch-and-Release” Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models. J. Pharm. Sci. 2018, in press.
  68. Ramakrishnan, V.; Mager, D. E. Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells. J. Pharmacol. Exp. Ther. 2018, 365 (3), 734–751.
  69. Rawson, T. M.; Charani, E.; Moore, L. S. P.; Gilchrist, M.; Georgiou, P.; Hope, W.; Holmes, A. H. Exploring the Use of C-Reactive Protein to Estimate the Pharmacodynamics of Vancomycin. Ther. Drug Monit. 2018, 40 (3), 315–321.
  70. Rees, V. E.; Yadav, R.; Rogers, K. E.; Bulitta, J. B.; Wirth, V.; Oliver, A.; Boyce, J. D.; Peleg, A. Y.; Nation, R. L.; Landersdorfer, C. B. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas Aeruginosa from Respiratory Infections of Cystic Fibrosis Patients. Antimicrob. Agents Chemother. 2018.
  71. Saccomani, M. P.; Thomaseth, K. The Union between Structural and Practical Identifiability Makes Strength in Reducing Oncological Model Complexity: A Case Study. Complexity 2018.
  72. Song, L.; Zhang, Y.; Jiang, J.; Ren, S.; Chen, L.; Liu, D.; Chen, X.; Hu, P. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanisti. Clin. Pharmacokinet. 2018, 57 (10), 1307–1323.
  73. Srivastava, S., Deshpande, D., Nuermberger, E., Lee, P.S., Cirrincione, K., Dheda, K. and Gumbo, T. The sterilizing effect of intermittent tedizolid for pulmonary tuberculosis. Clinical Infectious Diseases, 2018, 67(suppl_3), pp.S336-S341.
  74. Srivastava, S., Deshpande, D., Magombedze, G. and Gumbo, T. Efficacy versus hepatotoxicity of high-dose rifampin, pyrazinamide, and moxifloxacin to shorten tuberculosis therapy duration: there is still fight in the old warriors yet!. Clinical Infectious Diseases, 2018, 67(suppl_3), pp.S359-S364.
  75. Sukarnjanaset, W.; Wattanavijitkul, T.; Jarurattanasirikul, S. Evaluation of FOCEI and SAEM Estimation Methods in Population Pharmacokinetic Analysis Using NONMEM® Across Rich, Medium, and Sparse Sampling Data. Eur. J. Drug Metab. Pharmacokinet. 2018.
  76. Świerczek, A., Wyska, E., Pociecha, K., Baś, S. and Mlynarski, J. Influence of inflammatory disorders on pharmacokinetics of lisofylline in rats: implications for studies in humans. Xenobiotica, 2018.
  77. Tukulula, M.; Gouveia, L.; Paixao, P.; Hayeshi, R.; Naicker, B.; Dube, A. Functionalization of PLGA Nanoparticles with 1, 3-β-Glucan Enhances the Intracellular Pharmacokinetics of Rifampicin in Macrophages. Pharm. Res. 2018, 35 (6), 111.
  78. Uddayasankar, U., Lee, C., Oleschuk, C., Eschun, G. and Ariano, R.E. The pharmacokinetics and pharmacodynamics of carfentanil after recreational exposure: a case report. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018, 38(6), pp.e41-e45.
  79. Urmashev, B.A., Tursynbay, A.T., Temirbekov, A.N. and Amantayeva, A.B. Solving the Reverse Problems of Pharmacokinetics for a Linear Two-Compartment Model with Absorption. In 2018 IEEE 12th International Conference on Application of Information and Communication Technologies (AICT)(pp. 1-7). IEEE, 2018.
  80. Vaidya, T.; Straubinger, R. M.; Ait-Oudhia, S. Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer. Pharm. Res. 2018, 35 (5), 95.
  81. Wang, J., Jayne, J., Fukushima, L., Rao, A.P., D’Argenio, D.Z. and Beringer, P.M. Pharmacokinetics of tedizolid in plasma and sputum of adults with cystic fibrosis. Antimicrobial agents and chemotherapy, 2018, 62(9).
  82. Yadav, R.; Rogers, K. E.; Bergen, P. J.; Bulitta, J. B.; Kirkpatrick, C. M. J.; Wallis, S. C.; Paterson, D. L.; Nation, R. L.; Lipman, J.; Roberts, J. A. Optimization and Evaluation of Piperacillin plus Tobramycin Combination Dosage Regimens against Pseudomonas Aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. Antimicrob. Agents Chemother. 2018, 62 (5).
  83. Yang, Q. J.; Bukuroshi, P.; Quach, H. P.; Chow, E. C. Y.; Pang, K. S. Highlighting Vitamin D Receptor–Targeted Activities of 1α, 25-Dihydroxyvitamin D3 in Mice via Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling. Drug Metab. Dispos. 2018, 46 (1), 75–87.
  84. Zasowski, E. J.; Murray, K. P.; Trinh, T. D.; Finch, N. A.; Pogue, J. M.; Mynatt, R. P.; Rybak, M. J. Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin. Antimicrob. Agents Chemother. 2018, 62 (1).
  85. Zhu, X.; Shen, X.; Qu, J.; Straubinger, R. M.; Jusko, W. J. Multi‐scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells. CPT pharmacometrics Syst. Pharmacol. 2018, 7 (9), 549–561.
  86. Zhu, X.; Trueman, S.; Straubinger, R. M.; Jusko, W. J. Physiologically-Based Pharmacokinetic and Pharmacodynamic Models for Gemcitabine and Birinapant in Pancreatic Cancer Xenografts. J. Pharmacokinet. Pharmacodyn. 2018, 45 (5), 733–746.
  87. Zuur, M. A.; Pasipanodya, J. G.; van Soolingen, D.; van der Werf, T. S.; Gumbo, T.; Alffenaar, J.-W. C. Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs. Clin. Infect. Dis. 2018.